Initiating ADHD Treatment With a Nonstimulant

DATA UPDATE

Qelbree pediatric and adult dose optimization¹

Transitioning patients to a once-daily nonstimulant for ADHD.


INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

Please see full Important Safety Information to the top left.

A novel nonstimulant that works for attention-deficit/hyperactivity disorder (ADHD) in patients 6 years and older^1,2

✓ 24-hour exposure to medication in a single daily dose—can be dosed AM or PM^1,3

✓ Straightforward weekly titration to optimal dose in as little as 2 weeks¹

✓ Qelbree can be conveniently prescribed and refilled without a new prescription every month

Transitioning patients to once-daily Qelbree¹

Titrate weekly as needed to optimize ADHD symptom control¹

✓  Qelbree is prescribed once daily (AM or PM) for full 24-hour exposure^1,3
✓  Qelbree can be conveniently prescribed and refilled without a new prescription every month
✓  Qelbree has no known addiction potential or evidence of abuse^1,4,5
 

Qelbree is available in 3 capsule strengths¹             

^{Capsules shown are not actual size.}

Administration
Capsule can be taken whole or entire contents can be sprinkled over a spoonful of soft food (pudding or applesauce). Consume the mixture in its entirety, without chewing, within 15 minutes for pudding or within 2 hours for applesauce; do not store for future use.¹

• Capsules and their contents should not be cut, crushed, or chewed¹
• Can be taken with or without food¹

 Abbreviations: OS, end of study; OLE, open-label extension. 

IMPORTANT SAFETY INFORMATION

• Severe renal impairment: Initiate Qelbree at 100 mg once daily and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily

Please see full Important Safety Information to the top left.

Please see full Prescribing Information, including Boxed Warning.

Learn more about Qelbree, an extended-release, nonstimulant medication for ADHD: https://www.QelbreeHCP.com/

 
References: 

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 
2. Food and Drug Administration. Novel drug approvals for 2021. May 13, 2022. Accessed January 7, 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biologicalproducts/novel-drug-approvals-2021.
3. Data on file, Supernus Pharmaceuticals.
4. Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav. 1980;12:155-161.
5. Food and Drug Administration. Table of Prescription Stimulant Label Changes. May 10, 2023. Accessed July 13, 2023. https://www.fda.gov/media/168050/download

QBE.2024-0104